Long term efficacy of entecavir therapy on viral suppression in nucleoside-nave chronic hepatitis B patients
Jing-dong XIE,CHENRong,LIUYun-ye,Wei CAI,Hui WANG,GUOQing,GURui-ying,ZHOUXia-qiu,XIEQing
2014-01-01
Abstract:Objective Durable hepatitis B virus (HBV)DNA suppression is important to antiviral effectiveness in chronic hepatitis B (CHB). In this study,we analyzed the long-term efficacy and resistance profile of entecavir (ETV) monotherapy in 20 Chinese patients with nucleoside nave CHB treated for at least 5 years. Methods Twenty HBeAg positive patients with HBV DNA level 107 copies/mL and alanine aminotransferase (ALT)level 2-fold upper limit of normal (ULN)received ETV 0.5 or 1 mg/day for accumulated 5 years. Serum HBV DNA level,HBeAg status and HBsAg level were assessed at baseline and at year 1 ,2 ,3 ,4 and 5 . Gene sequencing was also conducted in the patients whose serum HBV DNA level > 300 copies/mL at year 5 . Results The ratio of HBV DNA undetectable (<300 copies/mL)for these 20 patients were 60% ,40% ,50% ,85% and 85% at year 1,2,3,4 and 5 respectively. The ratios of HBeAg loss were 15% ,15% ,20% ,30% and 65% at year 1,2,3,4 and 5,respectively. Three of 20 patients (15% )achieved HBeAgseroconversion at year 4 and 5 . Variables were compared between the patients whose serum HBV DNA < 300 copies/mL and those of patients > 300 copies/mL at week 48. Virological response rate was 100% and 66.7% at week 240 in the former's and the latter's,respectively;HBeAg seroconversion rate was 27.3% and 0 at week 240 in the former's and latter's, respectively. Virological response rate was 100% at week 240 in the patients whose ALT level 2-fold ULN,and was only 75% in the patients whose ALT level < 2-fold ULN;Meanwhile,the rate of HBeAg seroconversion was 37.5% and 0 in the former's and latter's. The rate of HBeAg seroconversion was 1 1 .1% at week 240 in the patients whose HBV DNA level>108 copies/mL at baseline,and was only 50% in the patients whose HBV DNA level <108 copies/mL at baseline,the statistics had significant difference (P<0.05). The mean serum HBsAg levels of the patients were (4.04±0.40)log10 IU/mL,(3.64±0.44)log10 IU/mL,(3.73±0.41)log10 IU/mL,(3.53±0.55)log10 IU/mL,(3.55±0.55)log10 IU/mL and (3.55±0.63)log10 IU/mL at baseline and at year 1,2,3,4 and 5,respectively. HBsAg levels had a greater mean reduction at year 1 (P= 0.005),3 (P= 0.005),4 (P= 0.009)and 5 (P= 0.018)compared with baseline, respectively. The HBsAg titers at baseline were significantly different between the patients whose HBeAg loss (3.95 ± 0.54)log10 IU/mL and HBeAg non-loss (4.20±0.48)log10 IU/mL at week 240 (P= 0.005). Non adverse effect was observed in this study. Conclusion These analysis demonstrates that long-term treatment of ETV monotherapy is effective in maintaining viral suppression. No ETV resistance substitution are detected in these patients.